ASCVD
Clinical trials for ASCVD explained in plain language.
Never miss a new study
Get alerted when new ASCVD trials appear
Sign up with your email to follow new studies for ASCVD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a single drug calm inflamed arteries in people with a common gene mutation?
Disease control Recruiting nowThis study tests whether the drug canakinumab can reduce inflammation in the blood vessels of people who have had a heart attack or a stent placed. It includes people with and without a specific genetic change called TET2 clonal hematopoiesis. The goal is to see if the drug lower…
Matched conditions: ASCVD
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 17, 2026 10:09 UTC
-
Arm cuff therapy may shield organs in High-Risk heart patients
Disease control Recruiting nowThis study tests whether a non-invasive treatment called remote ischemic conditioning (RIC) can reduce the risk of heart attacks, strokes, kidney problems, and death in people with very high-risk atherosclerotic cardiovascular disease (ASCVD). RIC involves briefly inflating a blo…
Matched conditions: ASCVD
Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug aims to melt artery plaque in heart patients
Disease control Recruiting nowThis study tests an experimental drug called ABP-745 in 200 adults with atherosclerosis (hardening of the arteries due to plaque buildup). The goal is to see if it can reduce plaque in the arteries better than a placebo. Participants will receive the drug or placebo for 52 weeks,…
Matched conditions: ASCVD
Phase: PHASE2 • Sponsor: Atom Therapeutics Co., Ltd • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
Massive trial tests which diabetes drug best shields heart and kidneys
Disease control Recruiting nowThis study aims to find out which of two common diabetes medications—SGLT2 inhibitors or GLP-1 receptor agonists—is better at preventing serious heart and kidney events in people with type 2 diabetes. About 6,000 adults with diabetes and heart disease or high risk will be randoml…
Matched conditions: ASCVD
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated May 06, 2026 16:02 UTC